Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 10, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date June 10, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,798 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 6,405 · Balance 17,798 F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.42 · Expires 2036-06-10 | Direct | 10,891 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Grant · Acquired 10,891 · Balance 10,891 F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 13, 2026 01:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 10,891 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001628280-26-043004 · wk-form4_1781312824.xml · derivative · entry 2 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,891 Underlying: Common Stock · 10,891 shares Expires 2036-06-10 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 10, 2026 Filed Jun 13, 2026 01:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-043004 · wk-form4_1781312824.xml · nonDerivative · entry 1 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,798 F1 · shares: Represents restricted stock units that vest on June 10, 2027, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| August 07, 2025 Filed Aug 11, 2025 20:09 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 4,912 | $23.67 | $116,267.04 |
DisclosureSEC source: 0001396814-25-000107 · wk-form4_1754942983.xml · nonDerivative · entry 1 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,393 Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 11,279 | $0.00 Strike: $24.34 | $0.00 |
DisclosureSEC source: 0001396814-25-000084 · wk-form4_1749845879.xml · derivative · entry 2 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,279 Underlying: Common Stock · 11,279 shares Expires 2035-06-11 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 11, 2025 Filed Jun 13, 2025 20:18 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 6,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-25-000084 · wk-form4_1749845879.xml · nonDerivative · entry 1 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,305 F1 · shares: Represents restricted stock units that vest on June 11, 2026, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| August 16, 2024 Filed Aug 19, 2024 12:25 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 1,512 | $13.25 | $20,034.00 |
DisclosureSEC source: 0001396814-24-000118 · wk-form4_1724070350.xml · nonDerivative · entry 1 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,142 Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 00:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 3,400 | $12.01 | $40,834.00 |
DisclosureSEC source: 0001396814-24-000106 · wk-form4_1723509190.xml · nonDerivative · entry 1 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,630 F1 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.75 to $12.35, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 1. Read SEC document |
| August 12, 2024 Filed Aug 13, 2024 12:43 UTC Amendment | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 3,400 | $12.01 | $40,834.00 |
DisclosureSEC source: 0001396814-24-000110 · wk-form4a_1723553015.xml · nonDerivative · entry 1 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,630 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.75 to $12.35, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote 1. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:14 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,179 | $0.00 Strike: $28.68 | $0.00 |
DisclosureSEC source: 0001396814-24-000082 · wk-form4_1718316863.xml · derivative · entry 2 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,179 Underlying: Common Stock · 12,179 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:14 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000082 · wk-form4_1718316863.xml · nonDerivative · entry 1 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,230 F1 · shares: Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| October 06, 2023 Filed Oct 11, 2023 20:46 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 30,967 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001396814-23-000071 · wk-form4_1697057191.xml · derivative · entry 1 BIGAL MARCELO · CIK 0001996637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,967 Underlying: Common Stock · 30,967 shares Expires 2033-10-06 F1 · derivative.exercise_date: The options vest in 36 equal successive monthly installments over the 36-month period following the date of grant, subject to the reporting person's continued service as a director. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.